17 Beta-hydroxysteroid dehydrogenase in human breast cancer: analysis of kinetic and clinical parameters. 1988

D Leszczynski, and S J Santner, and P D Feil, and R J Santen
Department of Medicine, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.

In this study, we assessed the rate of estradiol degradation via the 17 beta-hydroxysteroid dehydrogenase (HSD) enzyme in breast tumors from postmenopausal women. We initially studied the effects of time, level of enzyme activity, amount of tissue assayed, and substrate concentration on the linearity of conversion of estradiol to estrone in breast tumor homogenates. The reaction was demonstrated to be linear when less than 15% conversion of estradiol to estrone occurred over 30 min with homogenates produced from 2.5 mg of tissue. Detailed kinetic experiments demonstrated the presence of two classes of enzyme activity, one with high affinity and the other with low affinity. In 83% of the tumors examined, the high affinity form was present and had a median Km of 0.62 microM and Vmax of 82 nmol/g protein/h. In 29 tumors, HSD activity could be precisely quantified and correlated with clinical parameters. No statistically significant correlation of enzyme activity with estrogen receptor (r2 = 0.06) or progesterone receptor (r2 = 0.006) or with patient age could be detected (r2 = 0.001). In 12 additional tumors, activity exceeded 15% conversion of estradiol to estrone at 30 min and precise quantitation was not possible. The average content of progesterone receptor was similar for these 12 tumors as for the 19 with lower HSD activity. However, estrogen receptor content and patient age were lower in the group with high HSD activity. The finding of a high affinity form of HSD in this study provides support for the biological importance of this enzyme in breast cancer tissues.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004970 Estrone An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women. Folliculin (Hormone),Estrone, (+-)-Isomer,Estrone, (8 alpha)-Isomer,Estrone, (9 beta)-Isomer,Estrovarin,Kestrone,Unigen,Wehgen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015067 17-Hydroxysteroid Dehydrogenases A class of enzymes that catalyzes the oxidation of 17-hydroxysteroids to 17-ketosteroids. EC 1.1.-. 17 beta-Hydroxysteroid Dehydrogenases,Testosterone Dehydrogenases,17-Ketosteroid Reductases,17 Hydroxysteroid Dehydrogenases,17 Ketosteroid Reductases,17 beta Hydroxysteroid Dehydrogenases,Dehydrogenases, 17 beta-Hydroxysteroid,Dehydrogenases, 17-Hydroxysteroid,Dehydrogenases, Testosterone,Reductases, 17-Ketosteroid

Related Publications

D Leszczynski, and S J Santner, and P D Feil, and R J Santen
September 1982, The Journal of clinical endocrinology and metabolism,
D Leszczynski, and S J Santner, and P D Feil, and R J Santen
February 1992, International journal of cancer,
D Leszczynski, and S J Santner, and P D Feil, and R J Santen
October 1982, Journal of steroid biochemistry,
D Leszczynski, and S J Santner, and P D Feil, and R J Santen
November 1996, The Journal of clinical endocrinology and metabolism,
D Leszczynski, and S J Santner, and P D Feil, and R J Santen
August 1979, Steroids,
D Leszczynski, and S J Santner, and P D Feil, and R J Santen
December 1985, Journal of steroid biochemistry,
D Leszczynski, and S J Santner, and P D Feil, and R J Santen
September 1967, Acta endocrinologica,
D Leszczynski, and S J Santner, and P D Feil, and R J Santen
February 1999, Biochemical Society transactions,
D Leszczynski, and S J Santner, and P D Feil, and R J Santen
May 1984, Endocrinology,
D Leszczynski, and S J Santner, and P D Feil, and R J Santen
August 1990, Journal of steroid biochemistry,
Copied contents to your clipboard!